These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16887123)

  • 1. Extended-release niacin raises adiponectin and leptin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Atherosclerosis; 2007 Aug; 193(2):361-5. PubMed ID: 16887123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential increase in high-molecular weight adiponectin after niacin.
    Westphal S; Luley C
    Atherosclerosis; 2008 May; 198(1):179-83. PubMed ID: 17996241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipokines and treatment with niacin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Metabolism; 2006 Oct; 55(10):1283-5. PubMed ID: 16979396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
    Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
    Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased total and high-molecular weight adiponectin after extended-release niacin.
    Plaisance EP; Grandjean PW; Brunson BL; Judd RL
    Metabolism; 2008 Mar; 57(3):404-9. PubMed ID: 18249215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
    Gomaraschi M; Ossoli A; Adorni MP; Damonte E; Niesor E; Veglia F; Franceschini G; Benghozi R; Calabresi L
    Vascul Pharmacol; 2015 Nov; 74():80-86. PubMed ID: 26133666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV
    Int J Clin Pract; 2007 Nov; 61(11):1942-8. PubMed ID: 17935553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome.
    Lo J; Bernstein LE; Canavan B; Torriani M; Jackson MB; Ahima RS; Grinspoon SK
    Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E102-9. PubMed ID: 17374698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Termination of Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein Cholesterol and High Triglycerides: Impact on Global Health Study and decision to use extended-release niacin in elderly.
    Shil AB
    J Am Geriatr Soc; 2011 Dec; 59(12):2397-8. PubMed ID: 22188098
    [No Abstract]   [Full Text] [Related]  

  • 11. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
    Chow DC; Stein JH; Seto TB; Mitchell C; Sriratanaviriyakul N; Grandinetti A; Gerschenson M; Shiramizu B; Souza S; Shikuma C
    AIDS; 2010 Apr; 24(7):1019-23. PubMed ID: 20216298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of niacin on adiponectin levels in the adipocytes secretion in rabbits].
    Li J; Zhao SP; Yang J; Dong SZ; Zhou HN
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 32(3):480-4. PubMed ID: 17611329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial.
    Panahi Y; Hosseini MS; Khalili N; Naimi E; Soflaei SS; Majeed M; Sahebkar A
    Nutrition; 2016 Oct; 32(10):1116-22. PubMed ID: 27297718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia.
    Hu M; Yang YL; Masuda D; Yamashita S; Tomlinson B
    Dis Markers; 2015; 2015():154014. PubMed ID: 26063948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
    Sorrentino SA; Besler C; Rohrer L; Meyer M; Heinrich K; Bahlmann FH; Mueller M; Horváth T; Doerries C; Heinemann M; Flemmer S; Markowski A; Manes C; Bahr MJ; Haller H; von Eckardstein A; Drexler H; Landmesser U
    Circulation; 2010 Jan; 121(1):110-22. PubMed ID: 20026785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin stimulates adiponectin secretion through the GPR109A receptor.
    Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.